Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 6;12(24):7531.
doi: 10.3390/jcm12247531.

Indoleamine 2,3-Dioxygenase 1 (IDO1) in Kidney Transplantation: A Guardian against Rejection

Krzysztof Wiśnicki  1 , Piotr Donizy  2 , Agnieszka Hałoń  2 , Patryk Wawrzonkowski  1 , Dariusz Janczak  3 , Magdalena Krajewska  1 , Mirosław Banasik  1
Affiliations

Indoleamine 2,3-Dioxygenase 1 (IDO1) in Kidney Transplantation: A Guardian against Rejection

Krzysztof Wiśnicki et al. J Clin Med. .

Abstract

Kidney transplantation is a crucial treatment for end-stage kidney disease, with immunosuppressive drugs helping to reduce acute rejection rates. However, kidney graft longevity remains a concern. This study explores the role of indoleamine 2,3-dioxygenase 1 (IDO1) in kidney transplant immunology. IDO1 breaks down tryptophan, affecting immune cell behavior, primarily T-cells. The research focuses on both cellular and antibody-mediated immune responses, often causing graft damage. The study assessed IDO1 expression in renal transplant biopsies from patients with graft function decline, examining its connection to clinical parameters. A total of 121 biopsy samples were evaluated for IDO1 expression using immunohistochemistry. Patients were categorized as IDO1(+) positive or IDO1(-) negative based on immunoreactivity in tubular epithelium. Results showed a significant link between IDO1 expression and rejection incidence. IDO1(+) positive patients had lower rejection rates (32.9%) compared to IDO1(-) negative ones (62.2%) [p = 0.0017], with substantial differences in antibody-mediated rejection (AMR) (5.2% vs. 20%) [p = 0.0085] and T-cell mediated rejection (TCMR) (31.6% vs. 57.8%). These associations suggest that IDO1 may play a protective role in kidney transplant rejection. IDO1 modulation could offer novel therapeutic avenues to enhance graft survival. The study underscores IDO1 as a potential marker for rejection risk assessment, with its potential applications in personalized interventions and improved patient outcomes. Further research is needed to fully comprehend the mechanisms behind IDO1's immunomodulatory functions and its potential clinical translation.

Keywords: T-cell mediated rejection (TCMR); acute rejection; antibody-mediated rejection (AMR); immunosuppression; indoleamine 2,3-dioxygenase 1 (IDO1); kidney transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Enhanced immunoreactivity of IDO1 in tubular epithelium of renal graft; hematoxylin, 200×.
Figure 2
Figure 2
Enhanced immunoreactivity of IDO1 in tubular epithelium of renal graft; hematoxylin, 400×.
See this image and copyright information in PMC

References

    1. Kostro J.Z., Hellmann A., Kobiela J., Skóra I., Lichodziejewska-Niemierko M., Dębska-Ślizień A., Śledziński Z. Quality of Life After Kidney Transplantation: A Prospective Study. Transplant. Proc. 2016;48:50–54. doi: 10.1016/j.transproceed.2015.10.058. - DOI - PubMed
    1. Schoot T.S., Goto N.A., van Marum R.J., Hilbrands L.B., Kerckhoffs A.P.M. Dialysis or kidney transplantation in older adults? A systematic review summarizing functional, psychological, and quality of life-related outcomes after start of kidney replacement therapy. Int. Urol. Nephrol. 2022;54:2891–2900. doi: 10.1007/s11255-022-03208-2. - DOI - PMC - PubMed
    1. Milaniak I., Rużyczka E.W., Dębska G., Król B., Wierzbicki K., Tomaszek L., Przybyłowski P. Level of Life Quality in Heart and Kidney Transplant Recipients: A Multicenter Study. Transplant. Proc. 2020;52:2081–2086. doi: 10.1016/j.transproceed.2020.03.038. - DOI - PubMed
    1. Rodríguez Castellanos F.E., Domínguez Quintana F., Soto Abraham V., Mancilla Urrea E. Classification of Acute Rejection Episodes in Kidney Transplantation: A Proposal Based on Factor Analysis. Iran. J. Kidney Dis. 2018;12:123–131. - PubMed
    1. Wong T.C., Lo C.M., Fung J.Y. Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation. Expert Opin. Emerg. Drugs. 2017;22:123–136. doi: 10.1080/14728214.2017.1330884. - DOI - PubMed